Patent application number | Description | Published |
20080248028 | Immunoglobulin Variants Outside the Fc Region - The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application. | 10-09-2008 |
20080267979 | Anti-Glypican-3 Antibody - An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention. | 10-30-2008 |
20090010920 | Fc Variants Having Decreased Affinity for FcyRIIb - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 01-08-2009 |
20090053211 | Optimized Fc variants - The present invention relates to optimized Fc variants, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 02-26-2009 |
20090215991 | Optimized Fc Variants and methods for their generation - The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 08-27-2009 |
20100317834 | IgG Immunoglobulin Variants with Optimized Effector Function - The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes. | 12-16-2010 |
20110064727 | Immunoglobulin Variants Outside the Fc Region - The present invention relates to antibody variants outside the Fc region that alter binding affinity to one or more effector ligands, methods for their generation, and their therapeutic application. | 03-17-2011 |
20150098941 | Anti-Glypican-3 Antibody - An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention. | 04-09-2015 |
Patent application number | Description | Published |
20130156754 | Optimized Fc Variants and Methods For Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 06-20-2013 |
20130156758 | Optimized Fc Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 06-20-2013 |
20130209457 | Optimized Fc Variants - The present invention relates to a variant Fc region comprising an amino acid substitution at position 238 of the Fc region as compared to a human parent Fc region, wherein the variant Fc region comprises a 238D substitution, wherein the variant Fc region binds FcγRIIb with increased binding affinity compared to a human parent Fc region. | 08-15-2013 |
20130243762 | Optimized Fc Variants and Methods for Their Generation - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 09-19-2013 |
20130261289 | Optimized Fc Variants - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 10-03-2013 |
20130273043 | Optimized Fc Variants - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 10-17-2013 |
20130302315 | Optimized Fc Variants - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 11-14-2013 |
20140073768 | OPTIMIZED Fc VARIANTS - The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants. | 03-13-2014 |
20140294812 | FC VARIANTS THAT IMPROVE FCRN BINDING AND/OR INCREASE ANTIBODY HALF-LIFE - The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life. | 10-02-2014 |
20140370021 | OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 12-18-2014 |
20150071948 | NOVEL IMMUNOGLOBULIN VARIANTS - The present invention relates to Fc variants with optimized Fc ligand binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc ligand binding properties, and methods for using same. | 03-12-2015 |
20150079082 | OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION - The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants. | 03-19-2015 |
20150099863 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 04-09-2015 |
20150191533 | Fc VARIANTS WITH ALTERED BINDING TO FcRn - The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index. | 07-09-2015 |